In a housebound patient taking pregabalin 150 mg daily and as‑needed gabapentin 300 mg every 12 hours, should the gabapentin be discontinued and only pregabalin continued to avoid additive central nervous system depression?

Discontinue the Gabapentin Immediately

You should discontinue the gabapentin and continue only the pregabalin, as combining these two mechanistically identical medications provides no additional therapeutic benefit and significantly increases the risk of central nervous system depression, particularly in a housebound patient who may already be experiencing functional impairment from sedation and dizziness.

Why This Combination Makes No Clinical Sense

Gabapentin and pregabalin are both calcium channel α2-δ ligands that bind to the exact same receptor and inhibit neurotransmitter release through the identical mechanism 1. There is no pharmacological rationale for combining them - it's essentially like taking the same drug twice. The guidelines explicitly note that both produce "dose-dependent dizziness and sedation" 1, and the FDA label warns about respiratory depression risk, especially when combined with other centrally acting drugs 2.

The fact that your patient is housebound and unable to leave for appointments is a red flag that she may already be experiencing significant CNS depression from this regimen. The most common adverse effects leading to discontinuation in clinical trials were dizziness (4%) and somnolence (4%) 2, and these effects are clearly dose-dependent.

The Evidence Against Combination Therapy

While some research suggests pregabalin can work in patients who previously failed gabapentin 3, this refers to switching from one to the other, not combining them. A pharmacokinetic simulation study specifically examined transitioning from gabapentin to pregabalin and found that immediate discontinuation of gabapentin with initiation of pregabalin at the next scheduled dose was seamless and safe 4. The study showed no concerning drops in drug exposure during transition.

No guideline or study supports concurrent use of both gabapentinoids. In fact, the 2010 Mayo Clinic guidelines present them as alternative first-line options, not complementary therapies 1.

Practical Approach to This Patient

Step 1: Assess Current Functional Status

• Specifically ask about: daytime somnolence, falls, cognitive impairment, balance problems
• Document whether her inability to leave the house correlates with medication timing
• Check renal function (both drugs require dose adjustment in renal insufficiency) 1

Step 2: Immediate Medication Change

Discontinue gabapentin immediately and continue pregabalin 150 mg daily. Based on the pharmacokinetic data, this transition can be done abruptly without tapering the gabapentin 4. The pregabalin will maintain therapeutic coverage.

Step 3: Optimize Pregabalin Dosing

Her current pregabalin dose of 150 mg daily is actually at the lower end of the therapeutic range. Guidelines recommend:

• Starting dose: 150 mg/day in 2-3 divided doses
• Titrate to 300 mg/day after 1-2 weeks
• Maximum effective dose: 600 mg/day (though higher doses show more adverse effects without consistently better efficacy) 1

If her pain is inadequately controlled after stopping gabapentin, increase the pregabalin to 300 mg/day (150 mg twice daily) rather than adding back gabapentin. This is supported by evidence showing pregabalin 300 mg/day has an NNTB of 3.9-5.3 for 50% pain reduction in neuropathic pain conditions 5.

Step 4: Monitor for Improvement

Within 1-2 weeks of stopping gabapentin, you should see:

• Improved alertness and cognitive function
• Better mobility (potentially allowing her to leave the house)
• Maintained or improved pain control (especially if you titrate pregabalin up)

Addressing Patient Resistance

Your patient's resistance is understandable - she's been on this regimen "for a long time." However, you need to explain:

1. The medications work identically - taking both is like taking a double dose with no extra benefit
2. Her functional decline (being housebound) may be directly caused by excessive sedation from the combination
3. Safety concerns: The FDA specifically strengthened warnings about CNS depression and respiratory depression with gabapentinoids, especially in combination with other drugs 6
4. You're not taking away her pain control - you're optimizing it by using one agent at an appropriate dose

Critical Safety Considerations

• Renal function: Both drugs require dose reduction in renal insufficiency 1. If her creatinine clearance is reduced, even her current doses may be excessive
• Age: If she's elderly, lower starting doses and slower titration are recommended 1
• Other CNS depressants: Check for concurrent opioids, benzodiazepines, or alcohol use - these dramatically increase respiratory depression risk 2, 6
• Abuse potential: Pregabalin is Schedule V in the US; monitor for signs of misuse 1

What the Pain Management Prescriber Got Wrong

The original prescriber likely added gabapentin PRN when the pregabalin alone wasn't providing adequate relief. This reflects a fundamental misunderstanding of pharmacology - you cannot "rescue" with a drug that works through the same mechanism. The correct approach would have been to increase the pregabalin dose or add a medication from a different class (e.g., duloxetine, tricyclic antidepressant, or topical lidocaine for localized pain) 1.

Bottom line: Stop the gabapentin now. This combination is pharmacologically irrational and likely contributing to her functional decline.